Subconjunctival anti-VEGF may stop progression of corneal neovascularization

Subconjunctival injections of bevacizumab induced regression of recent-onset corneal neovascularization, according to a study.The double-masked, placebo-controlled clinical trial included 30 patients with corneal neovascularization attributed to various causes. Each patient received three 0.1-mL subconjunctival injections of 2.5-mg Avastin (bevacizumab, Genentech) or 0.9% saline solution at monthly intervals.

Full Story →